How ineffective hypertension control in subjects treated with angiotensin-converting enzyme inhibitors is related to polymorphisms in the renin-angiotensin-aldosterone system

European Journal of Pharmaceutical Sciences

Volumn 39, Issue 5, 2010, Pages 380-386

  Morales Suárez Varela, Maria M ^a,b,c   Mansego, Maria L ^d,e   Martín Escudero, Juan Carlos ^f   Llopis González, Agustín ^a,c   Chaves, Felipe Javier ^d,g   López Izquierdo, Raul ^f   Frutos Llanes, Raul ^f   Vicedo Cabrera, Ana M ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d Instituto Universitario IVI INCLIVA   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^g INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Hypertension; Polymorphisms; Renin angiotensin aldosterone system

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 77649184502     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.01.007     Document Type: Article

References (31)

1. Alonso-Moreno F.J., Llisterri Caro J.L., Rodriguez Roca G.C., Ferreiro Madueño M., González-Segura Alsina D., Divisón Garrote J.A., et al. Primary care physicians behaviour on hypertensive patients with poor blood pressure control. The PRESCAP 2006 study. Rev. Clin. Esp. 208 8 (2008) 393-399
2. Arnett D.K., Davis B.R., Ford C.E., Boerwinkle E., Leiendecker-Foster C., Miller M.B., et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion. Circulation 111 25 (2005) 3374-3383
3. Arnett D.K., Claas S.A., and Glasser S.P. Pharmacogenetics of antihypertensive treatment. Vascul. Pharmacol. 44 2 (2006) 107-118
4. Artigao L.M., Llavador J.J., Puras A., López Abril J., Rubio M.M., Torres C., et al. Evaluation and validation of Omron Hem 705 CP and Hem 706/711 monitors for self-measurement of blood pressure. Aten. Primaria. 25 (2000) 96-102
5. Association for the Advancement of Medical Instrumentation (AAMI). American National Standard for Electronic or Automated Sphygmomanometer (1987), AAMI, Arlington, Virginia
6. Atlas S.A. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J. Manage. Care Pharm. 13 8 Suppl. B (2007) 9-20
7. Banegas J.R., Rodriguez-Artalejo F., Ruilope L.M., Graciani A., Luque M., de la Cruz-Troca J.J., et al. Hypertension magnitude and management in the elderly population of Spain. J. Hypertens. 20 (2002) 2157-2164
8. Banegas J.R., Segura J., Ruilope L.M., Luque M., García-Robles R., Campo C., et al. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension 43 (2004) 1338-1344
9. Brugts J.J., den Uil C.A., Danser A.H.J., and Boersma E. The renin-angiotensin-aldosterone system: approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease. Cardiology 112 4 (2009) 303-312
10. Brugts J.J., de Maat M.P., Boersma E., Witteman J.C., van Duijn C., Uitterlinden A.G., Bertrand M., Remme W., Fox K., Ferrari R., Danser A.H., Simoons M.L., and EUROPA-PERGENE investigators. The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease. Cardiovasc. Drugs Ther. 23 2 (2009) 171-181
11. Ceconi C., Fox K.M., Remme W.J., Simoons M.L., Bertrand M., Parrinello G., Kluft C., Blann A., Cokkinos D., Ferrari R., and EUROPA Investigators; PERTINENT Investigators and the Statistical Committee. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc. Res. 73 (2007) 237-246
12. Cesari M., Kritchevsky S.B., Atkinson H.H., Penninx B.W., Di Bari M., Tracy R.P., et al. Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: Results from the trial of angiotensin converting enzyme inhibition and novel cardiovascular risk factors (TRAIN) study. Am. Heart. J. 157 2 (2009) 334
13. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42 (2003) 1206-1252
14. Danser A.H.J., and Schunkert H. Renin-angiotensin system gene polymorphisms: potential mechanisms for their association with cardiovascular diseases. Eur. J. Pharmacol. 410 (2000) 303-316
15. Danser A.H.J., Batenburg W.W., van den Meiracker A.H., and Danilov S.M. ACE phenotyping as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibition?. Pharmacol. Ther. 113 3 (2007) 607-618
16. Fahey T., Schroeder K., and Ebrahim S. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst. Rev. 1 (2005) CD005182
17. Foster C., McKinlay S., Cruickshank J.M., and Coats A.J. Accuracy of the Omron HEM 706 portable monitor for home measurement of blood pressure. J. Hum. Hypertens. 8 (1994) 661-664
18. Gonzalez J.R., Armengol L., Sole X., Guinó E., Mercader J.M., et al. SNPassoc: An R package to perform whole genome association studies. Bioinformatics 23 5 (2007) 644-645
19. Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25 (2007) 1105-1187
20. Izawa H., Yamada Y., Okada T., Tanaka M., Hirayama H., and Yokota M. Prediction of genetic risk for hypertension. Hypertension 41 5 (2003) 1035-1040
21. Llisterri Caro J.L., Rodriguez Roca G.C., Alonso-Moreno F.J., Lou Arnal S., Divisón Garrote J.A., Santos Rodríguez J.A., et al. Blood pressure control in Spanish hypertensive patients in primary health care centres. PRESCAP 2002 study. Med. Clin. (Barc.) 122 5 (2004) 165-171
22. Llisterri J.L., Rodríguez G.C., Alonso-Moreno F.J., Banegas Banegas J.R., González-Segura Alsina D., Lou Arnal S., et al. Control of blood pressure in Spanish hypertensive population attended in primary health-care, PRESCAP 2006 Study. Med. Clin. (Barc.) 130 (2008) 681-687
23. Martinez Perez S.R., Armando P.D., Molina Guerra A.C., Martí Pallarés M., and Martínez Martínez F. Relationship between cardiovascular risk factors and high blood pressure by community pharmacists in Spain. Pharm. World Sci. 31 3 (2009) 406-412
24. O'Brien E., Mee F., Atkins N., and O'Malley K. Short report: accuracy of the Dinamap portable monitor, model 8100 determined by the British Hypertension Society protocol. J. Hypertens. 11 (1993) 761-763
25. Pereira A.C., Mota G.F.A., Cunha R.S., Herbenhoff F.L., Mill J.G., and Krieger J.E. Angiotensinogen 235T allele "dosage" is associated with blood pressure phenotypes. Hypertension 41 1 (2003) 25-30
26. Perez Zamora S., Benitez Camps M., Dalfo Baque A., Piqueras Garré M., Losada Duval G., and Vila Coll M.A. Is the action taken by catalonian primary care doctors adequate in view of the insufficient reduction in blood pressure levels in hypertensive patients? DISEHTAC-2001 study. Aten. Primaria 40 10 (2008) 505-510
27. Rodriguez Roca G.C., Artigao Rodenas L.M., Llisterri Caro J.L., Alonso-Moreno F.J., Banegas Banegas J.R., Lou Arnal S., et al. Control of hypertension in elderly patients receiving primary care in Spain. Rev. Esp. Cardiol. 58 4 (2005) 359-366
28. Schelleman H., Stricker B.H., De Boer A., Kroon A.A., Verschuren M.W., Van Duijn C.M., Psaty B.M., and Klungel O.H. Drug-gene interactions between genetic polymorphisms and antihypertensive therapy. Drugs 64 (2004) 1801-1816
29. Wald D.S., Law M., Mills S., Bestwick J.P., Morris J.K., and Wald N.J. A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a beta-blocker on blood pressure reduction. Clin. Ther. 30 11 (2008) 2030-2039
30. WHO. World Health Organization-International Society of Hypertension. Guidelines for the management of hypertension. J. Hypertens. 17 (1999) 151-183
31. Wolf-Maier K., Cooper R.S., Banegas J.R., Giampaoli S., Hense H.W., Joffres M., et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 289 (2003) 2363-2369